In the face of escalating drug-resistant infections, the emergence of a new class of antibiotics offers a beacon of hope.Kinvard Bio, a pioneering biotech startup, is at the forefront of this revolutionary approach, leveraging advanced synthetic chemistry to develop novel compounds that target the bacterial ribosome.